Cancer cover under international medical insurance

The claim that tests everything else in the policy

Cancer is where an international medical policy either works or does not. It generates the highest costs, the longest treatment paths, the most cross-border movement, and the most claims that sit at the edge of what the wording contemplated. Nearly every other feature of the product — the annual limit, the area of cover, the pre-authorisation process, the acute and chronic definitions, the rules on what counts as proven treatment — is tested at once.

It is also the area where the marketing is least useful. Every insurer says cancer is covered, and every insurer means it. The differences are not in whether the benefit exists but in three places: what counts as screening rather than treatment, what counts as eligible treatment when the oncologist proposes something off-licence, and what happens when the treatment is not available where you live.

Treatment as a core benefit across the market

The starting point is genuinely reassuring, and it is the same everywhere.

Bupa Global states that once cancer is diagnosed it covers fees specifically related to planning and carrying out cancer treatment, and lists tests, chemotherapy and radiotherapy, diagnostic imaging, consultations and prescribed medicines. The benefit sits inside the plan tier rather than in a module.

Cigna markets full cancer care as a headline benefit of its core International Medical Insurance plan — not the optional out-patient module — capped at the plan's annual maximum on Silver and Gold, and paid in full on Platinum.

William Russell includes cancer treatment on all four of its personal plans, from the hospital-led Bronze plan upward, per its product information document dated 10 November 2025. From Silver it adds preventive cancer treatment and screening, and on Gold it adds a cash benefit on diagnosis of cancer — a lump sum triggered by diagnosis rather than a reimbursement of costs, which sits alongside the treatment benefit rather than replacing it.

That last structure is worth noting, because it is closer to a critical illness design than to an indemnity one and is doing a different job: covering the costs that are not medical bills. Whether it is worth the tier difference depends on what else the tier brings.

The practical implication of a core benefit capped at the annual maximum is that the annual maximum becomes the real cancer limit. On plans where oncology is paid in full the limit is irrelevant; on plans where it is not, a long treatment path crossing two policy years hits the annual reset and the inner limits, which is why annual benefit limits and inner limits matters more here than on any other benefit.

Screening is a different question from treatment

The most common misreading is to assume that a plan covering cancer treatment covers cancer screening. It usually does, but on different terms, in a different part of the policy, and after a different clock.

Bupa applies a 10-month waiting period to health screening and wellness benefits on its Global Health Plans, stated in its own pricing documentation, and one year on the Lifeline range. Bupa also positions genetic cancer screening as available only on its highest tier, which is a clear statement that the insurer regards predictive testing and treatment as economically different things.

William Russell adds preventive cancer treatment and screening from Silver rather than including it on the entry plan, and applies waiting periods and lifetime limits to the individual components — genetic testing for cancer and preventive surgery are both capped over a lifetime rather than annually, and both carry qualifying gates.

The general shape is: treatment cover is close to universal and begins early; screening cover is tier-dependent, waiting-period-dependent, often capped over a lifetime, and frequently subject to age and frequency rules. Anyone buying a plan because of a family history should read the screening benefit rather than the cancer benefit.

The eligibility rules that decide borderline claims

This is where oncology claims are actually won and lost, and it has almost nothing to do with the cancer benefit itself.

AXA publishes the clearest version of the rule. Cover is limited to conventional treatment: treatment established as best medical practice in the country where it is being given, clinically appropriate, and proven to be effective and safe through high-quality clinical trial evidence. Drugs must be licensed by the MHRA in the UK, the EMA in Europe outside the UK, or the FDA outside Europe, and must be used within the terms of that licence. Surgical procedures must appear in AXA's published schedule, with a route for procedures recognised by an authoritative medical body. There is no cover for complications arising from unproven or experimental treatment. Most policies across the market exclude experimental and unproven treatment outright — William Russell lists alternative and experimental treatment and therapies among its general exclusions, and NIMBL's wording excludes treatment that is unproven, awaiting clinical approval, not in standard clinical use, under clinical investigation, or used off-licence unless pre-authorised.

In most specialties that rule is unremarkable. In oncology it is the central issue, because oncology is the field where off-licence prescribing and trial participation are routine clinical practice rather than exceptional. A drug licensed for one tumour type and used for another on the strength of emerging evidence is off-licence use. A treatment offered within a trial is, by definition, not yet established. Both can be entirely appropriate medicine and outside the policy.

Two practical points follow. The first is that pre-authorisation is not a formality here — it is the mechanism by which you find out whether the proposed regimen is eligible before it is delivered, and NIMBL's wording explicitly allows pre-authorised off-licence use, which means the answer is sometimes yes if you ask. The second is that where a claim is refused on these grounds, the refusal turns on a definition rather than on the diagnosis, which changes how an appeal is framed — see declined IPMI claims and how to appeal.

Where cancer care crosses the acute and chronic boundary

Active treatment for a curable cancer is an acute episode and is covered as one. What follows it may not be.

Insurers define a chronic condition as one needing ongoing or long-term monitoring, ongoing control or relief of symptoms, rehabilitation or special training, or one that continues indefinitely or has no known cure. Long-term surveillance after treatment, maintenance therapy, and the management of late effects can each meet one of those limbs, and where a plan treats chronic conditions differently — for example capping in-patient treatment of chronic conditions at a stated number of days per admission, as AXA does at 120 — the terms change without the diagnosis changing.

For a cancer that is managed rather than cured, the whole treatment path may sit on the chronic side from the outset. This is the boundary that determines whether a policy remains useful five years after diagnosis, and it is set out in acute versus chronic conditions.

Evacuation for treatment, not just for emergencies

Most evacuation benefits are built around an emergency: the member needs urgent in-patient care and the local facilities cannot provide it. Cancer does not usually arrive that way. It arrives as a diagnosis, followed by a considered decision about where the best treatment is available.

Cigna's evacuation module is unusual in addressing this directly: evacuation, though not repatriation, is available for diagnostic tests or cancer treatment where its medical assistance service considers it appropriate. That is a materially broader trigger than an emergency admission, and it is a distinguishing feature worth checking for where local oncology provision is limited.

AXA's position runs the other way and is stated equally plainly: it will not pay where a member decides to travel elsewhere for treatment and the insurer believes the nearest medical facilities are adequate — and that expressly includes deciding to travel back to a country of residence for treatment. William Russell splits the function, offering a basic evacuation benefit as core and an optional upgrade that extends evacuation to advanced imaging and cancer treatment unavailable locally.

So the answer to "can I be moved somewhere better for my cancer treatment?" is: it depends whether your evacuation benefit is triggered by emergency or by appropriateness, and whether it was bought as core or as a module. The general mechanics are in the existing guide to medical evacuation and repatriation insurance, and the module question is covered in core cover versus optional modules.

Second opinions at the point of diagnosis

The most valuable thing an insurer provides in the first fortnight after a cancer diagnosis is often not money.

Bupa Global offers a Second Medical Opinion service to all customers, and AXA includes one alongside its virtual doctor service. Both are provided by third parties. Bupa states explicitly that its Global Virtual Care and Second Medical Opinion services are provided by a third party directly to the member and are not regulated by the Financial Conduct Authority or the Prudential Regulation Authority.

That regulatory point cuts two ways. It means the service sits outside the insurance contract, so it generally does not consume a benefit limit and, in AXA's case, is expressly excess-free. It also means it is not an insurance benefit you can enforce. Used at diagnosis — before a treatment plan is fixed and before pre-authorisation is sought — a second opinion is the cheapest way to test both the clinical proposal and its eligibility under the conventional-treatment rules. The services are compared in virtual GP and second medical opinion services.

What is arriving next: advanced therapy medicinal products

Advanced therapy medicinal products — cell and gene therapies — have started appearing as a named benefit line, including on Bupa's Lifeline documentation. They matter for three reasons: they are among the most expensive interventions in medicine, they are delivered at a small number of specialist centres, which makes area of cover and evacuation relevant, and they sit at precisely the boundary the licensing rules police.

An insurer that names them has decided how to treat them. An insurer that does not has not necessarily excluded them, but the answer will come from the general conventional-treatment and experimental-treatment rules, which is a less predictable place to find it. As these therapies move from trial to standard care in more indications, this line is worth watching on renewal documentation.

What to check on your own policy

Establish whether cancer treatment is paid in full or capped at the annual maximum, and if capped, what happens to a treatment path that crosses a renewal. Read the screening benefit separately from the treatment benefit, with its waiting period, its tier and its frequency and age rules. Find the conventional-treatment or eligible-treatment clause and read it as if you had been offered an off-licence drug, because that is the scenario it governs. Check whether evacuation is triggered by emergency or by unavailability of appropriate treatment. And find out what the plan pays once treatment moves from cure to management, which is the point at which the chronic definition takes over.